Wade T. Iams

Dr. Wade T. Iams from Vanderbilt Ingram Cancer Society Center, co-author of the case report on acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer.

Best podcasts with Wade T. Iams

Ranked by the Snipd community

Mar 11, 2025 • 6min

A Rare Genetic Shift That Helped Lung Cancer Evade Treatment

Dr. Wade T. Iams, a researcher from the Vanderbilt Ingram Cancer Society Center, dives into the complexities of lung cancer treatment. He discusses a groundbreaking case where a patient developed resistance to lorlatinib due to a rare genetic alteration, RUFY1-RET. This revelation emphasizes the critical role of advanced genetic testing and the necessity for personalized cancer treatments. As cancer evolves, understanding resistance mechanisms becomes vital for effective precision oncology.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app